Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, BioNTech to Sell Further 200 Million Covid-19 Vaccine Doses to U.S. Government

07/23/2021 | 07:24am EDT

By Robb M. Stewart

Pfizer Inc. and BioNTech SE have agreed to supply an additional 200 million doses of their Covid-19 vaccine to the U.S. government, bringing the total under their existing supply agreement to 500 million doses.

The additional doses that will be bought will help the U.S. government ensure broad vaccine access into next year, said Albert Bourla, chairman and chief executive of Pfizer.

The companies said they expect to deliver 110 million of the additional doses by the end of the year, and the remaining 90 million no later than April 30, 2022.

The U.S. government also has the option to buy an updated version of the vaccine to address potential variants as well as new formulations of the vaccine, if available and authorized, the companies said. Eligible U.S. residents will continue to receive the vaccine for free, under a government commitment for free access to Covid-19 vaccines.

The Pfizer-BioNTech Covid-19 vaccine hasn't been approved or licensed by the U.S. Food and Drug Administration, but the agency has authorized it for emergency use.

In June, Pfizer and BioNTech said they planned to provide the U.S. government with 500 million doses of their Covid-19 vaccine for donation to the world's poorest nations.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

07-23-21 0723ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 4.90% 372.65 Delayed Quote.357.13%
PFIZER, INC. -0.67% 44.47 Delayed Quote.21.62%
All news about BIONTECH SE
08:12aMODERNA : U.S. COVID-19 booster debate moves to FDA vaccine advisory committee
RE
07:00aMODERNA : U.S. COVID-19 booster debate moves to FDA vaccine advisory committee
RE
02:24aPFIZER : Hong Kong Assesses Pfizer-BioNTech's COVID-19 Jab In Booster Study
MT
09/16Pfizer-BioNTech, Moderna's Booster COVID-19 Shots Enters Real-Time Review in ..
MT
09/16UK Study to Mix Three COVID-19 Vaccine Doses in Adolescents
MT
09/16PFIZER : CEO Backs Booster Shots Ahead of FDA Committee Meeting
MT
09/16PFIZER : and BioNTech Covid Vaccine Gets Approval From Health Canada for Individ..
MT
09/16PFIZER : FDA Sees Current COVID-19 Vaccine Protocol as Still Effective Ahead of ..
MT
09/16PFIZER : FDA Says Currently Authorized COVID-19 Vaccines in the US Remain Effect..
MT
09/16Singapore Sees Lowest Unemployment Rate Since March 2020 in Q2; Job Vacancies..
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 16 863 M 19 863 M 19 863 M
Net income 2021 8 881 M 10 461 M 10 461 M
Net cash 2021 9 100 M 10 719 M 10 719 M
P/E ratio 2021 8,93x
Yield 2021 -
Capitalization 76 502 M 90 003 M 90 115 M
EV / Sales 2021 4,00x
EV / Sales 2022 3,25x
Nbr of Employees 2 500
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 316,75 €
Average target price 279,31 €
Spread / Average Target -11,8%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE357.13%90 003
GILEAD SCIENCES, INC.22.43%89 434
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.28.41%65 728
VERTEX PHARMACEUTICALS-20.83%48 539
BEIGENE, LTD.49.09%35 842